⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4696518 | 1.00 | — | — | |
| SCHEMBL15311105 | 0.80 | — | — | |
| SCHEMBL15311053 | 0.78 | MEN1 (0.32) | — | |
| SCHEMBL10865082 | 0.78 | — | — | |
| SCHEMBL14761931 | 0.78 | MEN1 (0.32) | — | |
| SCHEMBL10346117 | 0.78 | — | — | |
| SCHEMBL10865959 | 0.77 | ELANE (0.31) | — | |
| SCHEMBL13302716 | 0.77 | — | — | |
| SCHEMBL10345898 | 0.77 | ELANE (0.31) | — | |
| SCHEMBL7402592 | 0.74 | MME (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214931-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-12084414-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4309653-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Exithera Pharmaceuticals Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3102200-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | EXITHERA PHARMACEUTICALS INC (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220281813-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | EXITHERA PHARMACEUTICALS, INC. | 2022-09-08 | — | — | US | disclosed |
| US-11198673-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-10259785-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180244614-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | EXITHERA PHARMACEUTICALS, INC. | 2018-08-30 | — | — | US | disclosed |
| US-9994521-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170037003-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2017-02-09 | — | — | US | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| WO-2006108039-A2 | SUBSTITUTED AZETIDINONES | DAIAMED, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| EP-0337549-B1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO INC (US) | 1995-10-04 | — | — | EP | disclosed |
| US-5229381-A | Inhibitors of leukocyte enzyme elastase | MERCK & CO., INC. (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0481671-A1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1992-04-22 | — | — | EP | disclosed |
| EP-0337549-A1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1989-10-18 | — | — | EP | disclosed |
| US-4636567-A | CNS DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1987-01-13 | — | — | US | disclosed |
| US-4610821-A | CENTRAL NERVOUS SYSTEM, THYROTROPIN RELEASING HORMONE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-09-09 | — | — | US | disclosed |
| US-4564609-A | NERVOUS SYSTEM DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-01-14 | — | — | US | disclosed |
| EP-0123444-A1 | 4-Substituted-2-azetidinone compound, process of producing the compounds, and medicaments containing the compounds | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1984-10-31 | — | — | EP | disclosed |